An antineoplastic agent that inhibits BRAF kinase.

NCI: An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. (NCI Thesaurus)

An alpha(1A/1L)-adrenoceptor partial agonist.

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)

Chemotherapy protocol consisting of ... /Dacarbazine, Fluorouracil, Epirubicin/ used for treatment of neuroendocrine tumors.

Anti-CD40 antibody for treating hematological cancers.

Histone deacetylase inhibitor.

An HCV NS5A inhibitor.